Poulard takes part in AlgoTherapeutix’s 12M euros Series A round
Omnes’ Claire Poulard invests in a French biotech company developing a topical treatment for chemotherapy-induced peripheral neuropathy. Omnes and Bpifrance led AlgoTherapeutix’s 12 million euros Series A round that also included existing and new angel investors.
The Paris-based company will use the capital to fund the clinical development of its lead candidate, ATX01, up to clinical proof of concept. Over half of cancer patients treated with chemotherapy develop chemotherapy-induced peripheral neuropathy, or CIPN, and experience sensory symptoms and pain in the hands and feet, including loss of sensitivity, tingling, burning, cold and intense pain that can persist for months to years after treatment. There is currently no therapeutic approach that offers a satisfactory response to CIPN.
In a statement, Claire said the AlgoTherapeutix team “displayed scientific and operational strength in the early development of ATX01 and we are confident in their ability to establish the product’s clinical efficacy and safety going forward.”
Claire, who joined Omnes in 2015, was promoted earlier this year to principal. Other investments she has been involved with include Antabio, AgomAb Therapeutics and Newronika et Pherecydes Pharma. Claire has also monitored the firm’s investments in HORAMA and OCTIMET.
A Paris-based European investor in private equity and infrastructure, Omnes has 4 billion euros of assets under management.